Internal Reference Document
April 2026 | v2.0
Classification: CONFIDENTIAL
April 2026 | v2.0
Classification: CONFIDENTIAL
LP Segment — Revenue >$1.5B or Market Cap >$5B | FDA-approved specialty therapy | US commercial presence
| # | Company Ticker |
2024 Revenue Actual |
Market Cap Approx. |
HQ | CEO | In-Market Products | Treatment Area | Employees | Links |
|---|---|---|---|---|---|---|---|---|---|
| T1·01 | Eli LillyNOT IN CRM LLY |
~$45B |
~$700B |
Indianapolis, IN | David A. Ricks Chairman & CEO |
Mounjaro (T2D/Obesity)Verzenio (Breast Cancer)Taltz (Psoriasis) |
Diabetes/ObesityOncologyImmunologyNeuroscience |
~43,000 | ↗ Website |
| T1·02 | Novo NordiskNOT IN CRM NVO |
~$38B |
~$380B |
Bagsværd, DK / Plainsboro, NJ | Lars Fruergaard Jørgensen CEO |
Ozempic/Wegovy (T2D/Obesity)Rybelsus (T2D)Hemophilia portfolio |
Diabetes/ObesityRare BloodHormone |
~64,000 | ↗ Website |
| T1·03 | PfizerIN CRM PFE |
~$64B |
~$140B |
New York, NY | Albert Bourla PhD Chairman & CEO |
Eliquis (AF/VTE)Prevnar 20 (Pneumococcal)Vyndaqel (ATTR-CM)Ibrance (Breast Cancer) |
OncologyCVVaccinesRare Disease |
~88,000 | ↗ Website |
| T1·04 | Merck & Co.NOT IN CRM MRK |
~$64B |
~$255B |
Rahway, NJ | Robert M. Davis Chairman & CEO |
Keytruda (Oncology)Gardasil (HPV)Welireg (RCC/VHL)Lagevrio (COVID-19) |
OncologyVaccinesCVRare Disease |
~72,000 | ↗ Website |
| T1·05 | AbbVieIN CRM ABBV |
~$56B |
~$310B |
North Chicago, IL | Robert A. Michael Chairman & CEO |
Skyrizi (Psoriasis/IBD)Rinvoq (RA/AD/IBD)Botox (Migraine)Vraylar (Psychiatry) |
ImmunologyOncologyNeuroscienceAesthetics |
~50,000 | ↗ Website |
| T1·06 | Janssen/J&JIN CRM JNJ |
~$57B pharma segment |
~$370B parent |
New Brunswick, NJ | Jennifer Taubert EVP Worldwide Chairman |
Darzalex (Multiple Myeloma)Tremfya (Psoriasis/PsA)Erleada (Prostate Cancer) |
OncologyImmunologyNeuroscienceCV |
~134,000 | ↗ Website |
| T1·07 | AstraZenecaIN CRM AZN |
~$54B |
~$230B |
Cambridge, UK / Wilmington, DE | Pascal Soriot CEO |
Tagrisso (NSCLC)Farxiga (HF/CKD)Imfinzi (Lung/Bladder) |
OncologyCV/RenalRespiratoryRare Disease |
~89,000 | ↗ Website |
| T1·08 | NovartisIN CRM NVS |
~$50B |
~$210B |
Basel, CH / East Hanover, NJ | Vas Narasimhan MD CEO |
Entresto (Heart Failure)Cosentyx (Psoriasis/SpA)Kisqali (Breast Cancer) |
CVImmunologyOncologyNeuroscience |
~78,000 | ↗ Website |
| T1·09 | SanofiNOT IN CRM SNY |
~$48B |
~$130B |
Paris, FR / Bridgewater, NJ | Paul Hudson CEO |
Dupixent (AD/Asthma)Aubagio (MS)Kevzara (RA) |
ImmunologyRare DiseaseNeurologyVaccines |
~91,000 | ↗ Website |
| T1·10 | Bristol Myers SquibbIN CRM BMY |
~$48B |
~$100B |
New Brunswick, NJ | Christopher Boerner PhD CEO |
Eliquis (AF/VTE)Opdivo (Oncology)Reblozyl (Anemia) |
OncologyHematologyCVImmunology |
~34,000 | ↗ Website |
| T1·11 | TakedaNOT IN CRM TAK |
~$31B |
~$45B |
Tokyo, JP / Cambridge, MA | Christophe Weber CEO |
Entyvio (IBD)Takhzyro (HAE)Adcetris (Lymphoma) |
GIRare DiseaseOncologyNeuroscience |
~49,000 | ↗ Website |
| T1·12 | Boehringer IngelheimNOT IN CRM Private |
~$28B |
Private |
Ingelheim, DE / Ridgefield, CT | Hubertus von Baumbach Chairman |
Jardiance (T2D/HF)Ofev (IPF)Spevigo (GPP) |
CV/MetabolicRespiratoryImmunologyOncology |
~53,000 | ↗ Website |
| T1·13 | Gilead SciencesIN CRM GILD |
~$28B |
~$110B |
Foster City, CA | Daniel O'Day Chairman & CEO |
Biktarvy (HIV)Veklury (COVID-19)Trodelvy (Cancer) |
HIVOncologyLiver DiseaseInflammation |
~18,000 | ↗ Website |
| T1·14 | GSKIN CRM GSK |
~$37B |
~$80B |
London, UK / Philadelphia, PA | Emma Walmsley CEO |
Shingrix (Shingles)Dovato (HIV)Nucala (Asthma) |
VaccinesHIVRespiratoryOncology |
~71,000 | ↗ Website |
| T1·15 | AmgenIN CRM AMGN |
~$34B |
~$170B |
Thousand Oaks, CA | Robert A. Bradway Chairman & CEO |
Repatha (CV)Prolia/Xgeva (Bone)Lumakras (NSCLC) |
OncologyCVBoneInflammation |
~27,000 | ↗ Website |
| T1·16 | Genentech/RocheIN CRM RHHBY |
~$25B US pharma est. |
~$200B parent |
South San Francisco, CA | Teresa Graham CEO Genentech |
Ocrevus (MS)Hemlibra (Hemophilia A)Tecentriq (Cancer) |
OncologyNeuroscienceRare DiseaseOphthalmology |
~100,000 | ↗ Website |
| T1·17 | EMD Serono / Merck KGaANOT IN CRM MKKGY |
~€21B parent total |
~$50B parent |
Darmstadt, DE / Rockland, MA | Belén Garijo CEO Merck KGaA |
Mavenclad (MS)Bavencio (Oncology)Gonal-f/Pergoveris (Fertility) |
NeurologyOncologyFertilityImmunology |
~64,000 | ↗ Website |
| # | Company Ticker |
2024 Revenue Actual |
Market Cap Approx. |
HQ | CEO | In-Market Products | Treatment Area | Employees | Links |
|---|---|---|---|---|---|---|---|---|---|
| T2·01 | Teva PharmaceuticalNOT IN CRM TEVA |
~$16B |
~$20B |
Tel Aviv, IL / Parsippany, NJ | Richard Francis CEO |
Austedo (TD/HC)Ajovy (Migraine)Copaxone (MS) |
NeuroscienceRespiratoryBiosimilars |
~37,000 | ↗ Website |
| T2·02 | ViatrisIN CRM VTRS |
~$15B |
~$12B |
Canonsburg, PA | Scott A. Smith CEO |
EpiPen (Anaphylaxis)Breyna (Asthma)Broad generics |
CVRespiratoryOncologyGenerics |
~37,000 | ↗ Website |
| T2·03 | Otsuka PharmaceuticalIN CRM 4578.T |
~$14B parent |
~$25B |
Tokyo, JP / Princeton, NJ | Makoto Inoue President |
Abilify Maintena (Schizophrenia)Jynarque (ADPKD)Rexulti (MDD/AD) |
NeuroscienceNephrologyOncology |
~34,000 | ↗ Website |
| T2·04 | RegeneronNOT IN CRM REGN |
~$14B |
~$80B |
Tarrytown, NY | Leonard S. Schleifer MD PhD Co-founder/CEO |
Dupixent (with Sanofi)Eylea (Wet AMD)Libtayo (Cancer) |
ImmunologyOphthalmologyOncologyRare Disease |
~14,000 | ↗ Website |
| T2·05 | Astellas PharmaNOT IN CRM 4503.T |
~$11B |
~$18B |
Tokyo, JP / Northbrook, IL | Naoki Okamura CEO |
Xtandi (Prostate Cancer)Padcev (Bladder Cancer)Prograf (Transplant) |
OncologyUrologyTransplant |
~15,000 | ↗ Website |
| T2·06 | CSL BehringNOT IN CRM CSL.AX |
~$11B parent |
~$90B parent |
King of Prussia, PA | Paul McKenzie CEO CSL |
Hizentra/Privigen (PID)Haegarda (HAE)Idelvion (Hemophilia B) |
ImmunologyHematologyTransplant |
~32,000 | ↗ Website |
| T2·07 | Vertex PharmaceuticalsNOT IN CRM VRTX |
~$11B |
~$110B |
Boston, MA | Reshma Kewalramani MD CEO |
Trikafta (CF)Casgevy (SCD/β-Thalassemia) |
CFPainRare DiseaseGene Therapy |
~5,000 | ↗ Website |
| T2·08 | Daiichi SankyoIN CRM 4568.T |
~$10B |
~$55B |
Tokyo, JP / Basking Ridge, NJ | Sunao Manabe CEO |
Enhertu (HER2+ Cancers)Savaysa (AF/VTE)Injectafer (Iron Deficiency) |
OncologyCV |
~17,000 | ↗ Website |
| T2·09 | SandozNOT IN CRM SDZ |
~$10.4B |
~$32B |
Basel, CH / Princeton, NJ | Richard Saynor CEO |
Hyrimoz (Adalimumab biosimilar)Rixathon (Rituximab biosimilar)Broad generics |
BiosimilarsGenerics |
~22,000 | ↗ Website |
| T2·10 | BiogenIN CRM BIIB |
~$9.5B |
~$15B |
Cambridge, MA | Christopher A. Viehbacher CEO |
Leqembi (with Eisai, Alzheimer's)Tysabri (MS)Spinraza (SMA) |
NeuroscienceRare DiseaseBiosimilars |
~7,500 | ↗ Website |
| T2·11 | Bausch HealthNOT IN CRM BHC |
~$9B |
~$3B |
Laval, QC / Bridgewater, NJ | Thomas J. Appio CEO |
Xifaxan (IBS-D/HE)Bausch + Lomb portfolio |
GIOphthalmologyDermatology |
~21,000 | ↗ Website |
| T2·12 | ViiV HealthcareIN CRM Private JV |
~$8B |
Private |
London, UK / Research Triangle Park, NC | Deborah Waterhouse CEO |
Dovato (HIV)Cabenuva (HIV, long-acting)Apretude (PrEP) |
HIV |
~3,000 | ↗ Website |
| T2·13 | UCBNOT IN CRM UCB.BR |
~$7B |
~$25B |
Brussels, BE / Smyrna, GA | Jean-Christophe Tellier CEO |
Bimzelx (Psoriasis)Vimpat (Epilepsy)Cimzia (Crohn's/RA) |
ImmunologyNeurology |
~9,000 | ↗ Website |
| T2·14 | OrganonIN CRM OGN |
~$6B |
~$4B |
Jersey City, NJ | Kevin Ali CEO |
Nexplanon (Contraception)Follistim (Fertility)Biosimilars portfolio |
Women's HealthBiosimilars |
~10,000 | ↗ Website |
| T2·15 | EisaiNOT IN CRM 4523.T |
~$5.5B |
~$15B |
Tokyo, JP / Nutley, NJ | Haruo Naito CEO |
Leqembi (Alzheimer's)Lenvima (Cancer)Fycompa (Epilepsy) |
NeurologyOncology |
~11,000 | ↗ Website |
| T2·16 | Sun PharmaNOT IN CRM SUNPHARMA |
~$6B |
~$45B |
Mumbai, IN / Princeton, NJ | Dilip Shanghvi Managing Director |
Ilumya (Psoriasis)Winlevi (Acne)Odomzo (BCC) |
DermatologyOncologyOphthalmologyGenerics |
~42,000 | ↗ Website |
| T2·17 | GenmabNOT IN CRM GMAB |
~$3.1B |
~$17B |
Copenhagen, DK / Princeton, NJ | Jan van de Winkel PhD CEO |
Darzalex (MM, with J&J)Tepkinly (DLBCL)Kesimpta (MS, with Novartis) |
OncologyImmunology |
~1,800 | ↗ Website |
| # | Company Ticker |
2024 Revenue Actual |
Market Cap Approx. |
HQ | CEO | In-Market Products | Treatment Area | Employees | Links |
|---|---|---|---|---|---|---|---|---|---|
| T3·01 | IncyteNOT IN CRM INCY |
~$4B |
~$15B |
Wilmington, DE | Hervé Hoppenot CEO |
Jakafi (Myelofibrosis/PV)Opzelura (AD/Vitiligo)Monjuvi (DLBCL) |
OncologyDermatologyInflammation |
~2,500 | ↗ Website |
| T3·02 | Jazz PharmaceuticalsIN CRM JAZZ |
~$4B |
~$7B |
Dublin, IE / Palo Alto, CA | Bruce Cozadd Chairman & CEO |
Xywav (Narcolepsy)Rylaze (ALL)Epidiolex (Epilepsy) |
NeuroscienceOncology |
~2,500 | ↗ Website |
| T3·03 | IpsenNOT IN CRM IPN.PA |
~$3.5B |
~$10B |
Paris, FR / Cambridge, MA | David Loew CEO |
Somatuline (NET)Cabometyx (RCC/HCC)Dysport (Spasticity) |
OncologyRare DiseaseNeuroscience |
~5,700 | ↗ Website |
| T3·04 | LundbeckNOT IN CRM LUN.CO |
~$3B |
~$8B |
Copenhagen, DK / Deerfield, IL | Charl van Zyl CEO |
Vyepti (Migraine)Rexulti (with Otsuka, MDD)Abilify Maintena (with Otsuka) |
Neuroscience |
~5,800 | ↗ Website |
| T3·05 | BioMarinNOT IN CRM BMRN |
~$2.8B |
~$14B |
San Rafael, CA | Alexander Hardy CEO |
Voxzogo (Achondroplasia)Palynziq (PKU)Naglazyme (MPS VI) |
Rare Disease |
~3,700 | ↗ Website |
| T3·06 | Sobi (Swedish Orphan Biovitrum)NOT IN CRM SOBI.ST |
~$2.5B |
~$10B |
Stockholm, SE / Waltham, MA | Guido Oelkers CEO |
Doptelet (ITP)Elocta/Alprolix (Hemophilia)Kineret (Autoinflammatory) |
HematologyImmunologyRare Disease |
~2,000 | ↗ Website |
| T3·07 | United TherapeuticsIN CRM UTHR |
~$2.3B |
~$12B |
Silver Spring, MD | Martine Rothblatt PhD Chairman & CEO |
Tyvaso (PAH)Remodulin (PAH)Orenitram (PAH) |
Pulmonary HypertensionOrgan Transplant |
~1,100 | ↗ Website |
| T3·08 | Neurocrine BiosciencesNOT IN CRM NBIX |
~$2.2B |
~$15B |
San Diego, CA | Kevin Gorman PhD CEO |
Ingrezza (TD)Orilissa (Endometriosis) |
NeuroscienceEndocrinology |
~1,800 | ↗ Website |
| T3·09 | Sarepta TherapeuticsNOT IN CRM SRPT |
~$2B |
~$8B |
Cambridge, MA | Douglas Ingram CEO |
Elevidys (DMD gene therapy)Exondys 51/Vyondys 53 (DMD) |
Rare DiseaseGene Therapy |
~3,500 | ↗ Website |
| T3·10 | Alnylam PharmaceuticalsNOT IN CRM ALNY |
~$1.8B |
~$30B |
Cambridge, MA | Yvonne Greenstreet MBChB CEO |
Onpattro/Amvuttra (hATTR)Givlaari (AHP)Oxlumo (PH1) |
Rare DiseaseRNAi Therapeutics |
~2,500 | ↗ Website |
| T3·11 | Ferring PharmaceuticalsNOT IN CRM Private |
~$1.8B |
Private |
Saint-Prex, CH / Parsippany, NJ | Per Falk CEO |
Rebyota (C. difficile)Firmagon (Prostate Cancer)Menopur (Fertility) |
GIUrologyReproductive Medicine |
~6,500 | ↗ Website |
| T3·12 | Madrigal PharmaceuticalsNOT IN CRM MDGL |
~$958M 2025 (launch 2024) |
~$12B |
Conshohocken, PA | Bill Sibold CEO |
Rezdiffra (MASH, first FDA-approved) |
Liver/Metabolic (MASH) |
~600 | ↗ Website |
(1) Revenue and market cap: Approximate figures primarily reflecting 2024 fiscal year actuals. Madrigal revenue shown is 2025 due to mid-2024 product launch. (2) IN CRM status: 19 of 46 accounts are already tracked in Genflare CRM. (3) Acquired entities: Alexion is represented via AstraZeneca row (acquired 2021); Shire via Takeda (acquired 2019). (4) Corporate structure: Genentech is US commercial entity; parent is Roche Group. ViiV Healthcare is a GSK/Pfizer/Shionogi JV. Boehringer Ingelheim and Ferring are privately held. (5) Tier placement: Primarily by revenue band. Some companies (Sun Pharma, Alnylam, Madrigal) have market caps significantly above their revenue-based tier. (6) New companies added April 2026: EMD Serono/Merck KGaA, Sandoz, Sun Pharma, Genmab, Madrigal Pharmaceuticals.